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Abstract  
The role of Tertiary lymphoid structures (TLS) in cancer has recently been illustrated and 
revisited using mouse models. Joshi et al. describe regulatory T (Treg) cell infiltration and 
functional heterogeneity of TLS in lung tumors. Finkin et al. report that inflammation-
associated TLS serve as niche for tumor progenitor cells, which may lead to recurrence in 
hepatocellular-carcinoma. 
 
Tertiary lymphoid structures (TLS) are ectopic lymphoid formations that reflect lymphoid 
neogenesis occuring at sites of inflammation in non lymphoid tissues [1]. TLS exhibit 
characteristics of secondary lymphoid organs. They are composed of a T cell zone containing 
mature DC-Lamp+ dendritic cells (DC), adjacent to a B cell zone which includes a typical 
germinal center (GC) comprising B cells embedded within a network of follicular DC. High 
Endothelial Venules (HEV) surround TLS, enabling lymphocyte entry from the blood. TLS 
develop during infectious diseases, autoimmune and inflammatory disorders, graft rejection, 
in solid tumors and in inflamed tissues upon exposure to environmental stimuli. TLS density 
correlates with protective outcome or disease exacerbation, depending on the context. In 
human cancers, TLS can be found in primary tumors [2] and in metastatic sites [1]. In all 
human cancer types tested so far, TLS density correlated with patient’s favorable clinical 
outcome, and recent developments also suggest that TLS formation is associated with cancer 
patients’ response to immunotherapy (reviewed in [1]). These observations, together with the 
coordinated CD8
+
 memory T cell and Th1 gene signature detected in the immune infiltrates of 
lung tumors with high TLS densities, have led to the concept that TLS allow the initiation 
and/or maintenance of a local and systemic adaptive immune response that protects patients 
against tumor invasion and metastasis [3].  However, animal models that could enable a 
comprehensive understanding of the function of TLS in cancer were lacking, with the 
exception of the signs of lymph node like-vasculature detected in B16 melanoma tumors [4]. 
Two recent articles using genetically engineered mouse models (GEMM) of lung cancer [5] 
and hepatocellular carcinoma (HCC) [6] shed light on TLS regulation and function and 
provide new insight on their role in cancer development. 
Joshi et al. [5] investigated the relationships between Treg cells and TLS using a GEMM 
where lung adenocarcinoma is initiated by intratracheal instillation of lentiviruses expressing 
firely luciferase fused to a portion of Ovalbumin and Cre recombinase that activates 
oncogenic KRas and deletes the tumor suppressor Trp53 in lung epithelial cells. The authors 
observed that most tumors analyzed (93%) contained TLS similar to TLS detected in human 
cancers. In this model, tumor development is dependent on the presence of Treg cells: 
depletion of Treg cells leads to exacerbation of the disease and increased tumor infiltration by 
CD4
+
 and CD8
+
 T cells and macrophages. Joshi et al. found that most Treg cells in tumors 
were located within the Tumor-Associated (TA)-TLS, mainly in the T cell area. Ova-specific 
TCR transgenic CD8
+
T cells preferentially localized in the T cell areas of TA-TLS, formed 
immunological synapses with DC and proliferated. Localized depletion of Treg cells via intra-
tumor injection of diphtheria toxin (Treg cells carried a Foxp3-DTR allele) led to increased T 
cell proliferation in TA-TLS consistent with the idea that TLS-Treg cells regulate local anti-
tumor responses. This evidence supports the notion that TA- TLS are sites where tumor-
specific T cell responses are generated, and furthermore, that endogenous anti-tumor immune 
responses are inhibited by Treg cells within these structures.  In accordance with these 
findings, elevated numbers of Treg cells in TLS correlate with poor survival of breast cancer 
patients [7].  
Finkin et al. [6]developed an inflammation-driven HCC model by expressing constitutively 
the active form of IKK-B in hepatocytes to activate the NF-B pathway, a situation that 
occurs in common forms of chronic hepatitis in humans [6, 8].  Similar to ectopic lymphoid 
structures (ELS) observed in human livers with hepatitis, ELS in these mice developed in the 
non-tumor zones of the inflamed liver, their aspect ranging from vague follicular aggregation 
to GC-containing follicles. Interestingly, small clusters of hepatocytes expressing E cadherin 
and several markers of HCC progenitor cells were found inside the ELS. These clusters 
progressively coalesced within the follicle boundary, egressed from the TLS and eventually 
grew as HCC in all IKK expressing livers. Deletion of Rag1 in 
IKK resulted in lack of ELS formation and attenuated 
hepatocarcinogenesis, suggesting that the formation of the ELS microniche for progenitor 
cells was dependent on the adaptive immune system. Lymphoid neogenesis is dependent on 
lymphotoxin receptor (LTR) signaling. Analysis of the cells expressing LTR in 
microdissected ELS revealed a switch from T and B lymphocytes in early forming structures 
to hepatocyte progenitors in advanced large ELS, suggesting that ELS provide paracrine LT 
signals to early progenitor cells which could then be replaced by an autocrine signal. Injection 
of LTR-Ig was associated with diminished intra-ELS progenitor cells and HCC burden. 
Analysis of ELS in human liver with hepatitis associated with human HCC revealed the 
presence of HCC progenitor cells. In a series of 82 surgically treated patients with HCC [8], 
ELS density score, as well as intensity of expression of an ELS 12-gene signature comprising 
lymphoid and myeloid attracting chemokines, were associated with increased risk for late 
recurrence and a trend toward decreased overall survival after HCC resection (6). 
These two studies suggest new roles for lymphoid structures in cancer. Joshi et al. 
demonstrate the presence of tumor-specific T cells within TA-TLS in an autochthonous 
mouse model of lung cancer, showing that TLS are sites for the generation of anti-tumor 
response immunity. A detailed characterization of Treg cell localization in cancers where the 
presence of Treg cells is associated with negative (Figure 1A) or positive [9] prognosis may 
provide insight into the roles of these cells during tumor progression. Finkin et al. show that 
hepatitis-associated ELS can provide a niche to support growth of tumor progenitor cells 
(Figure 1B).  How to reconcile this result with the numerous lines of evidence that tumor-
associated TLS correlate with good prognosis in human solid cancers ? Of note, the same 12-
gene signature associated with recurrence after surgical resection in HCC correlates with 
better patient survival in human colorectal carcinoma (10) suggesting that the tumor-
associated TLS and the hepatitis-associated TLS share common features. Indeed one may 
postulate that ELS persisting in inflammed hepatic tissue at distance of the primary tumor 
have a different function than the anti-tumoral TLS developing during the slow process of 
tumorigenesis (Figure 1). In viral associated HCC TLS persist despite infection suggesting a 
loss of their protective role. Of note, Hepatitis C viral infection correlates with 
lymphomagenesis in some patients [11]. One major issue now is to find whether ELS niches 
for tumor progenitor cells can be found in other inflammed organs than the liver and be 
associated to cancer recurrence in other cancers than HCC,  a concept which would need to 
re-visit the current litterature. These findings add complexity to our understanding of TLS that 
prompts further study of these dynamic structures. 
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Figure 1.  Putative pro-tumoral roles for TLS in cancer. A. Treg located in Tumor Associated-
TLS control the extent and activation CD4
+
 and CD8
+
 T cell infiltrates. TLS support a 
protective anti-tumor response (left). High TLS infiltration by Treg may correlate with tumor 
escape, in cancers where Treg are associated with poor prognosis (right). This situation 
remains speculative since TA-TLS density is associated with good prognostic value in many 
human cancer types at different stages. B. ELS in non tumoral liver with hepatitis support 
growth of HCC progenitor cells, tumor recurrence and correlate with poor survival.  Genes 
associated with inflammation including NFB are expressed in the non tumoral liver (red). 
Hepatitis-associated ELS may serve as a “field” for carcinogenesis and provide a niche to 
produce de novo malignant tumors independently from the removed primary tumor (white). 
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